ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (NASDAQ: INHX), a biopharmaceutical company focused on the development of products to treat and prevent serious infectious diseases, announced today that it has commenced enrollment in a Phase I clinical trial of FV-100, an orally bioavailable nucleoside analogue being developed to treat herpes zoster (shingles). The single ascending dose study is being conducted in the United States under an exploratory Investigational New Drug Application and will evaluate the safety and pharmacokinetics of three doses of FV-100 in 24 healthy volunteers.
